Skip to main content
. 2014 Oct 15;74(6):1261–1270. doi: 10.1007/s00280-014-2604-8

Fig. 2.

Fig. 2

Maximum percent change from baseline observed at any point during the study in the sum of longest diameter (SLD) of target lesions relative to axitinib area under the plasma concentration–time curve at steady-state (AUCss) during a cycle 1 (AUCss-cycle1) and b the entire time on study (AUCss-study); although no patients in the study had a RECIST-defined complete response, two patients had target lesions that became unmeasurable during axitinib treatment (−100 % change)